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Background: Recombinant hemagglutinin (rHA) is the active component in Flublok®; a trivalent influenza vaccine
produced using the baculovirus expression vector system (BEVS). HA is a membrane bound homotrimer in the
influenza virus envelope, and the purified rHA protein assembles into higher order rosette structures in the final
formulation of the vaccine. During purification and storage of the rHA, disulfide mediated cross-linking of the trimers
within the rosette occurs and results in reduced potency. Potency is measured by the Single Radial Immuno-diffusion
(SRID) assay to determine the amount of HA that has the correct antigenic form.
Results: The five cysteine residues in the transmembrane (TM) and cytoplasmic (CT) domains of the rHA protein from
the H3 A/Perth/16/2009 human influenza strain have been substituted to alanine and/or serine residues to produce
three different site directed variants (SDVs). These SDVs have been evaluated to determine the impact of the TM and
CT cysteines on potency, cross-linking, and the biochemical and biophysical properties of the rHA. Modification of these
cysteine residues prevents disulfide bond cross-linking in the TM and CT, and the resulting rHA maintains potency for
at least 12 months at 25°C. The strategy of substituting TM and CT cysteines to prevent potency loss has been
successfully applied to another H3 rHA protein (from the A/Texas/50/2012 influenza strain) further demonstrating the
utility of the approach.
Conclusion: rHA potency can be maintained by preventing non-specific disulfide bonding and cross-linked multimer
formation. Substitution of carboxy terminal cysteines is an alternative to using reducing agents, and permits room
temperature storage of the vaccine.
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Licensed, seasonal influenza vaccines available in the
United States include trivalent and quadrivalent inacti-
vated vaccines and a live attenuated influenza vaccine
produced in embryonated chicken eggs [1,2], a cell cul-
ture based trivalent vaccine produced in Madin Darby
Canine Kidney (MDCK) cells [3,4], and most recently a
recombinant trivalent vaccine (Flublok) produced using
the baculovirus-insect cell system [5-7]. Flublok vaccine* Correspondence: isrivastava@ProteinSciences.com
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unless otherwise stated.has several distinct advantages over other flu vaccines
including high purity of the HA protein, and absence of
antibiotics, preservatives, gelatin, and egg proteins.
HA, the most abundant and immunogenic surface
antigen of the influenza virus, is responsible for mediat-
ing viral attachment by binding to sialic acid residues on
the host cell surface, and for fusing the viral envelope to
the host cell membrane [8]. The HA protein is a homo-
trimer extending 135 Å from the viral membrane, and
consists of a stem-like region formed by three helices,
one from each monomer, and a globular head domain
containing antigenic epitopes. These two domains formhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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bromelain cleavage to determine its crystal structure
[9-11]. The TM domain sequence has a propensity to
form alpha-helical oligomers in model systems [12-14]
and this tendency may extend to the alpha-helices of the
stem region [15]; however, the structure of this domain,
as well as the conformation of C-terminal amino acids
of the CT, has not been determined.
Flublok includes three rHA proteins (full length without
signal peptide) that are highly purified (≥90%) using our
universal purification process, and are updated according
to the annual influenza strain selection process [5]. By
comparison, the whole virus vaccines produced using the
traditional egg based system are chemically inactivated
with either formaldehyde or beta-propiolactone (BPL) and
partially purified by either column chromatography or su-
crose gradient ultracentrifugation and filtration [16-18].
Split and subunit vaccines produced using both the egg
and cell culture systems include a detergent extraction
step, as well as an additional sucrose gradient or alterna-
tive purification step, to further reduce the lipid and con-
taminating protein content [16-18]. Despite considerable
variation in the manufacturing processes and purity, the
quantification or potency of the HA proteins produced ei-
ther in eggs or in BEVS is determined using the SRID
assay [19,20]. The SRID based potency assay, in use since
1978, is required to standardize HA content in inactivated
licensed flu vaccines by the FDA. The SRID assay usesA
B
Figure 1 A and B Amino acid sequence of the TM and CT domains. A
cytoplasmic tail (CT) domains in the hemagglutinin protein. Protein sequen
B, and H3 subtypes have been included and the cysteine residues highligh
variants of H3 A/Perth and H3 A/Texas rHA are shown. The position of the
for the TM and CT domains are underlined and double underlined, respectstrain specific anti-HA antibodies to quantify HA trimer
in the presence of the surfactant Zwittergent 3–14.
Purified wild-type rHA proteins, particularly H3 rHAs,
show an apparent initial loss of potency in the SRID
assay before leveling off within typically four weeks after
production. In the case of H3 rHA from the A/Perth/16/
2009 influenza strain included in the 2010–2011, and
2011–2012 Flublok vaccines, this apparent initial loss of
potency is as high as 40% and is correlated with an in-
crease in disulfide bond cross-linking, and the oxidation
of at least one conserved cysteine residue at position 549
of the primary sequence in the CT domain [21]. HA
proteins derived from human influenza viruses can con-
tain 2–5 cysteine residues in the TM and CT domains
depending on the subtype (Figure 1A) in addition to
twelve conserved cysteine residues located in the ecto-
domain which form six sets of disulfide bonds based on
X-ray crystal structure analysis and are required for
proper folding [22-24]. These cysteine residues have
been implicated in membrane fusion, viral assembly and
replication [25-28]. More recent studies have examined
the importance of the TM and CT cysteine residues on
thermal stability, heterotypic protection in mice, and
other virological features [29-32]. In the context of influ-
enza viruses, these cysteines in HA proteins are modified
with palmitic acid which may be important for biological
function. While the baculovirus-insect cell system supports
palmitoylation [33,34], such reversible, post-translational. Shown is a sequence alignment of the transmembrane (TM) and
ces from different human influenza strains belonging to the H1,
ted. B. The amino acid sequences of the wild-type and site directed
cysteine residues and the modifications are indicated. The sequences
ively.
Table 1 Starting and final purified yields for rHA proteins
rHA Starting yield Purified yield
% of wild-type % of wild-type
Wild-type 100 100




*SDV contains modifications C64S, C76S in the ectodomain of the protein.
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dicate that at least one of the two C-terminal cysteine is
partially free and undergoes oxidation [21].
In this study, we evaluated the role of the TM and CT
cysteine residues on the thermal stability as determined by
DSF, functional stability as determined by potency, antige-
nicity, and tertiary and quaternary structure of the H3 rHA
protein from the A/Perth/16/2011(H3 A/Perth) influenza
strain. All or a portion of the TM and CT cysteine residues
were substituted with either serine or alanine to produce
SDV rHA proteins. Our results demonstrate that this cyst-
eine substitution strategy can prevent an apparent potency
loss associated with disulfide mediated cross-linking, but
does not impact the expression, purification, folding, or
thermal stability of the molecule. Hemagglutination inhib-
ition, an assay used to determine the antigenic identity of
the vaccine viruses, has been used to show that the SDV
rHAs are antigenically similar to wild type rHA, and
that the cysteine substitution strategy does not impact
the antigen specific antibody responses in mice upon
immunization. The SDV rHAs are presented to the im-
mune system in the same quaternary structural form as the
wild-type rHA based on the comparability of the rosette
structure as determined by negative stain electron micros-
copy data. Finally, the cysteine substitution strategy has
been applied to another H3 rHA derived from the A/
Texas/50/2012 (H3 A/Texas) influenza strain with compar-
able results demonstrating that the approach can be applied
to address in vitro potency loss in H3 rHAs caused by the
formation of non-native disulfide bonds.
Results
Comparable expression and purification of the wild-type
and site directed variants
To examine the role of the cysteine residues located in
the TM and CT of the H3 A/Perth rHA protein, alanine
or serine substitutions were introduced into the wild-
type gene by site directed mutagenesis. Three different
SDVs were produced having two, three, and five cysteine
substitutions. They are referred to by the number of
cysteine substitutions or as 2Cys, 3Cys and 5Cys, re-
spectively (Figure 1B). Alanine was selected based on its
small size, similar hydrophobicity, and lack of chemistry
including hydrogen bonding. A cysteine to serine substi-
tution was made at position 523 in the 2Cys SDV based
on amino acid sequence alignments consistently showing
a serine at the equivalent position of HA proteins from
H1 and B subtypes (Figure 1A). As a control in this
study, a pair of conserved cysteine residues in the ecto-
domain known to form a disulfide bond, C64 and C76,
was disrupted by substitution with serine residues. Fi-
nally, to verify the relative potency findings obtained
with the H3 A/Perth 5Cys SDV rHA in this study, the
same strategy was used to replace all five TM/CTcysteine residues with alanine residues in the H3 A/
Texas rHA protein (Figure 1A and B).
The universal purification process for the wild-type rHA
was applied to the SDV rHA proteins without modifica-
tion. The expression level for the control SDV replacing
the two conserved and paired cysteines in the ectodomain
was too low to purify (Table 1). The potency of the soluble
rHA in the supernatant fraction was determined in the
SRID assay and was used to establish the starting yield.
The final yield after purification was determined using the
total protein results obtained by the BCA assay corrected
for the rHA purity determined by SDS-PAGE. The results
provided in Table 1 show that the starting and purified
yields for the 2Cys, 3Cys, and 5Cys SDV rHA proteins
relative to the wild-type rHA were equivalent or better
compared to the wild-type rHA protein.
Purity of rHA was determined by reducing SDS-PAGE.
The full length rHA proteins migrates as monomers
(HA0) having an approximate molecular weight of 62 kDa
(Figure 2A) under denaturing and reducing conditions.
The purity of the rHA proteins exceeds 99%.
rHA folding and activity were unaffected by substitutions
of the TM/CT cysteines
The trypsin resistance assay provides a qualitative assess-
ment of the folded state of the rHA protein. All the trypsin
recognition sites are masked in the correctly folded full-
length, HA trimer with the exception of one site located
toward the end of the stem region. As a result, properly
folded rHA protein is cleaved by trypsin into HA1 and
HA2, while denatured or mis-folded rHA degrades in the
presence of trypsin. Each rHA was trypsin treated with
and without heat denaturation and analyzed by reducing
SDS-PAGE alongside the untreated rHA with and without
heat denaturation (Figure 2B). All rHAs were resistant to
trypsin digestion and the trypsin resistance profiles ob-
tained for the SDV rHAs were comparable to that of the
wild-type rHA. In the presence of trypsin, the monomeric
rHA band (~60 kDa) was cleaved into HA1 and HA2 that
migrated as ~55 kDa and ~25 kDa proteins, respectively
(Figure 2B, lane 2). Boiling the rHA sample prior to tryp-
sin treatment denatured the protein and resulted in diges-
tion of the rHA by trypsin (Figure 2B, lane 4).
Figure 2 A and B SDS-PAGE purity and trypsin resistance gels for the H3 rHA proteins. A. Each rHA protein was loaded in duplicate to
give 1 μg total protein per lane. The samples were separated using 4-12% gradient Nu-PAGE gels and stained with Coomassie Blue. Molecular
weights of the proteins standards are shown. B. Shown are the reducing SDS-PAGE gels from the trypsin resistance assay. Each H3 rHA protein
was analyzed neat (Lane 1), after trypsin treatment (Lane 2), after heat treatment (Lane 3), and after heat and trypsin treatment (Lane 4). The
trypsin enzyme is loaded as a control and molecular weights of the protein standards are shown. HA1 and HA2 are indicated by arrows.
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tionally active forms of the protein, they were evaluated
in a hemagglutination assay using the wild-type H3 rHA
protein as control. Agglutination of red blood cells re-
quires the HA trimers to be organized in higher order
(rosette) structures. The globular head of the rHA trimer
forms a receptor binding site for terminal sialic acids on
red blood cells. The arrangement of trimers in a rosette
structure results in a lattice like structure of the bound
cells which do not settle out. Unbound cells settle out
and produce a button like or halo pattern of cells as ob-
served in negative controls (Figure 3A). The HA activity
of the H3 SDV rHAs were within 2–4 -fold of the HA
activity of the wild-type H3 rHA (Table 2).
Particle size is unaffected by cysteine substitutions
The particle size of the H3 rHA proteins was determined
by dynamic light scattering (DLS), and the results for the
volume mean diameter are provided in Table 3. The meanvolume diameter for the wild-type H3 rHA, and the 5Cys
and 3Cys SDV H3 rHAs are comparable (average 37.2 ±
2.1). In contrast, the mean volume diameter of the 2Cys
SDV H3 rHA was consistently larger in size (average
50.5 ± 1.8) and may be due to the alternative cysteine to
serine substitution in this SDV. Despite this difference, the
mean volume diameter of the particles observed for the
wild-type and SDV H3 rHAs by DLS (range 30–50 nm) was
consistent with the size of rosettes visible by EM [35,36].
The morphology of the rosettes was determined by
electron microscopy (EM). For this analysis, aliquots of
rHA protein samples stored for 2.5 month at 25°C were
submitted to Paragon Bioservices for electron micros-
copy. Representative EM images are shown in Figure 3B.
Rosette size, estimated to be approximately 30–50 nm,
and spike densities were similar in the EM images for
the wild-type H3 rHA and the SDVs.
SEC was performed to determine the homogeneity of
the preparations. The SEC elution profiles were similar
Figure 3 A and B Hemagglutination activity and negative stain electron microscopy of the H3 rHA proteins. A. The hemagglutination
assay was performed in 96-well u-bottom plates. The rHA proteins were assayed in triplicate at an initial concentration of 1 μg/mL loaded in the
left-most lane. Two-fold serially dilutions were performed across the plate in PBS, and equal volume 0.5% guinea pig red blood cells added. Endpoints
are denoted by dotted lines. B. The rHA proteins were stored at 25°C for 2.5 month at the time of EM analysis. The bar represents 100 nm.
Table 3 Volume mean diameter by DLS for wild-type and
Cys SDV H3 rHAs
Sample
name
Volume mean diameter (nm)
Day 0 Day 7 Day 28 Average
Wild-type 38.9 39.2 39.6 39.2 ± 0.4
5Cys 36.5 36.3 38.8 37.2 ± 1.4
3Cys 35.5 33.5 36.3 35.1 ± 1.4
2Cys 52.6 49.7 49.3 50.5 ± 1.8
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mary peak (average 29.39 ± 0.26) and the extrapolated
MWs (average 2,505 kDa ± 113 kDa) were similar for all
the rHAs. In addition, the extrapolated numbers of tri-
mers per rosette for the wild-type rHA and SDV rHAs
remained constant [11,12] suggesting that the cysteine
substitution did not affect the assembly of the trimers
into rosettes.
Both the wild type H3 rHA and 5 Cys SDV rHA were
analyzed by SEC UPLC before and after treatment withFigure 4 A-4C SEC-HPLC elution profiles, SEC-UPLC elution profiles, a
A. The SEC-HPLC elution profiles for the wild-type and SDV rHA proteins ov
rHA proteins. The # of trimers per rosette was estimated using the extrapolate
before (solid lines) and after (dotted lines) Zwittergent 3–14 pre-treatment are
temperature (Tm) was determined by DSF, and the second derivative thermal1% Zwittergent 3–14, a surfactant which converts rHA ro-
settes into the trimeric form. In the absence of Zwittergent
treatment, the wild-type and 5Cys SDV rHAs gave a single
broad peak by SEC with a retention time of approximately
3 minutes (Figure 4B). Pre-treatment of a 5Cys SDV rHA
with 1% Zwittergent 3–14 prior to SEC-UPLC analysis
shifted the broad peak to a narrower peak having a re-
tention time of 3.8 minutes. In contrast, the SEC-UPLC
profile for the wild-type rHA pre-treated with 1%
Zwittergent 3–14 resulted in multiple peaks with retentionnd thermal denaturation curves using DSF for the rHA proteins.
erlay. The retention times and extrapolated MWs are similar for the
d MW and a trimer MW of ~210 kDa. B. The SEC-UPLC elution profiles
shown in for the wild-type (left) and 5Cys SDV rHA (right). C. The melting
denaturation curves are shown for each rHA.
Table 4 Melting temperatures for wild-type and Cys SDV
H3 rHAs using DSF
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the presence of disulfide cross-linked multimers that are
not disrupted by the Zwittergent treatment in the wild-
type rHA. In contrast, the 5Cys SDV rHA does not have
disulfide mediated cross-linked structures and completely
shifts to a trimeric conformation upon treatment with 1%
Zwittergent 3–14.Thermal stability of rHA is unaffected by cysteine
substitutions in the TM and CT domains
The wild-type H3 rHA and Cys SDV H3 rHAs were an-
alyzed from 25°C to 99°C by DSF in the presence of a
molecular rotor dye (ProteoStat, Enzo Life Sciences) to
determine thermal stability. Fluorescence intensity was
monitored as a function of temperature and a single,
large cooperative unfolding was observed for each pro-
tein (Figure 4C). These data showed that Tms of SDV
rHA were all similar to the wild-type H3 rHA (Table 4),
and these differences in the Tms are not statistically sig-
nificant. Since the thermal stability of the SDVs as
determined by DSF was quite similar to the wild-type
rHA, this data further supports that the effect ofFigure 5 Potency determined by SRID for the wild-type and SDV rHA
storage and the potency measured at different time points by SRID. Shown
H3 A/Perth rHA in the study.cysteine substitutions on the overall structure of the
rHA is minimal.
Cysteine modifications affect potency loss, cross-linking,
and hydrophobicity
The wild-type H3 rHA and Cys SDV H3 rHAs were
stored at 25°C and potency by SRID and cross-linking by
SDS-PAGE were monitored. The potency was determined
by SRID on the day of final purification (day 0), day 7, day
14 or 21, and day 28, and after approximately 2.5, 6, 9, and
12 months. The results were plotted relative to the day 0
results for wild-type rHA, as well as, for each H3 SDV
rHA (Figure 5). The relative potencies of the 5Cys and
3Cys SDV H3 rHAs showed little change over time and
were significantly improved compared to the wild-type
and 2Cys SDV H3 rHA proteins. Based on the results, the
loss in potency decreases with the number of cysteine sub-
stitutions in the order WT> 2Cys > 3Cys > 5Cys.
Figure 6A shows the reducing and non-reducing SDS-
PAGE data obtained on days 0 and 28 of the study. Under
non-reducing conditions, rHA proteins typically migrate
as monomers and cross-linked oligomers which form a
ladder of higher molecular weight bands. The primary full-
length HA0 migrates at approximately 62 kDa, and dimer
and trimer migrate at approximately 120 and 180 kDa, re-
spectively. rHA proteins migrating above the 210 kDa
marker are due to the formation of higher order cross-
linked structures. The cross-linking is disulfide mediated
based on the SDS-PAGE profiles obtained under reducing
conditions which show predominantly monomeric rHA
(Figure 2A,B and Figure 6A).
The day 0 results show essentially no disulfide mediated
cross-linking by non-reducing SDS-PAGE for the 5Cysproteins stored at 25°C. The rHA proteins were placed at 25°C
are the potency results plotted relative to the day 0 value for each
Figure 6 A and B Non-reducing and reducing SDS-PAGE gels and densitometry for rHA proteins on days 0 and 28. A. Each rHA (~2.5 μg) was
analyzed by SDS-PAGE under non-reducing (N-R) and reducing (Red) conditions on days 0, 7, 14 or 21, and 28. Shown are gels obtained on day 0 (top)
and on day 28 (bottom). Densitometry was performed on the non-reducing lanes on the left-hand-side of each gel using the Carestream software
program, and the corresponding intensity profiles are shown on the right. B. The intensities of individual bands in the non-reducing SDS-PAGE gel
profiles were measured using the Carestream software program. The ratio of intensities for cross-linked bands migrating above the 70 kDa marker to
the un-cross-linked monomeric band migrating at ~70 kDa was calculated for each rHA and time point and plotted as function of storage time below.
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show evidence of cross-linked dimer, trimer and higher
order oligomers. After 1 month at 25°C, the 5Cys SDV
shows no sign of cross-linking, and the 3Cys SDV shows a
relatively small amount (approximately 15%) of cross-linkeddimer and trimer compared to an extensive increase in
cross-linking for the 2Cys SDV (approximately 63%) and
the wild-type rHA (approximately 72%) during the same
time period. A loss of intensity of HA0 (~60 kDa) is ob-
served for both the 2Cys and the wild-type rHA as a result
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mains comparable on days 0 and 28 for the 3Cys and 5Cys
SDVs. Thus, the decrease in cross-linking observed with
the number of cysteine substitutions in the TM/CT corre-
lates with the corresponding increase in the relative potency
for these SDVs.
The intensities of the individual bands in the SDS-
PAGE gels were measured at each time point in the
study, and the ratio of intensities of the cross-linked
forms to the un-cross-linked rHA (HA0) was deter-
mined for each rHA. These ratios were plotted as a
function of time (Figure 6B). It is evident that cross-
linking steadily increased for the wild-type H3 rHA and
the 2Cys SDV for up to 14 days and then stabilized. A
slight increase in cross-linking was observed for the
3Cys SDV on day 28, while no cross-linking was ob-
served for the 5Cys SDV during the study period.
The RP-HPLC profiles for the wild-type and 2Cys
SDV H3 rHAs are comparable, but different from the
RP-HPLC profiles for the 3Cys and 5Cys H3 SDV rHAs
(Figure 7). The 3Cys and 5Cys SDV H3 rHAs elute as a
single peak between 5.7-5.9 minutes, while the wild-type
and 2Cys SDV H3 rHAs elute in three separate peaks
(labeled 1–3) between 6–9 minutes. The elution time for
the first peak is very similar for all the three SDVs (5.7-
5.9 minutes), while the first peak for the wild-type elutes
slightly later (6.2 minutes). Additionally, retention times
for peaks 2 and 3 are slightly shorter for the 2Cys com-
pared to the wild-type rHA. By day 28, the three peaks
decrease in intensity and broaden for both the wild-type
and 2Cys SDV rHA suggesting a change in the conform-
ation of the rHA. In contrast, the profiles for the 3Cys
and 5Cys SDVs showing a single peak are similar at the
beginning and end of the study with one exception. A
leading tail on the elution peak for the 3Cys rHA is ob-
served on day 28, and coincides with the appearance ofFigure 7 RP-HPLC profiles for the H3 rHA proteins. Each H3 rHA was a
and 28 time points are provided. rHAs were incubated with 25 mM DTT fo
onto a Poros R1 column and an acetonitrile gradient applied.cross-linked rHA by SDS-PAGE on day 28 for the 3Cys
SDV. These results suggest that 3Cys SDV is effective in
reducing the disulfide mediated cross-linking, but all five
cysteine substitutions of the 5Cys SDV are required to
completely eliminate disulfide mediated cross-linking
and prevent potency loss.
The marked improvement in relative potency and the
lack of disulfide mediated cross-linking for the 5Cys SDV
in this study was confirmed for another 5Cys SDV rHA
and corresponding wild-type rHA derived from the H3 A/
Texas influenza strain. These rHA proteins were purified
and stored at two temperatures, 5°C and 25°C. Potency by
SRID, cross-linking by SDS-PAGE, and hydrophobicity by
RP-HPLC were monitored monthly up to 12 months
(Figure 8).
Antigenicity is unaffected by cysteine substitutions in the
TM and CT domains
To determine the antigenicity of the rHA proteins, the
hemagglutination inhibition (HAI) assay was performed
using two different polyclonal antisera. In addition, the
CBER reference antigen for H3 A/Perth/16/2009 HA
(lot# 70) was also included in the assay for comparison
with rHA proteins. Specific binding of the antibodies to
different antigenic sites in the HA proteins interferes
with the ability of the HA protein to agglutinate red
blood cells and forms the basis of the HAI assay. The
HAI endpoint or titer, the reciprocal of the last dilution
of antiserum that completely inhibits hemagglutination,
was determined for each rHA protein using both anti-
sera and compared to the CBER reference HA antigen
in Table 5. Using both antisera, the HAI endpoints of
the Cys SDV H3 rHA were equivalent or within 2-fold
of the wild-type H3 rHA and the CBER reference anti-
gen for H3 A/Perth HA. The results confirm that cyst-
eine substitutions introduced into the TM and CTnalyzed in duplicate. Representative chromatograms from the day 0
r at least 30 minutes prior to analysis. ~25 μg of each rHA was injected
Figure 8 A-C Experimental data for H3 A/Texas 5Cys SDV and wild-type rHA stored at 5°C and 25°C. Potency by SRID, cross-linking by
SDS-PAGE, and hydrophobicity by RP-HPLC were monitored monthly for 12 months. A. Shown are the potency results obtained at each time
point for the rHA proteins stored at 5°C (top graph) and 25°C (bottom graph). For each rHA, the potency results are plotted relative to the day 0
value. B. Shown are the non-reducing and reducing SDS-PAGE results obtained on day 0 and after 12 months for the sets of wild-type and 5Cys
SDV rHA proteins stored at 5°C and 25°C. C. Shown are the RP-HPLC profiles obtained on day 0 and 12 months for the sets of wild-type and 5Cys
SDV rHA proteins stored at 5°C and 25°C.
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Table 5 HAI titers for wild-type and Cys SDV H3 rHAs
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antigenic sites.
Antigen-specific antibody production is unaffected by
cysteine substitutions in the TM and CT domains
A comparative study was performed in mice using the
5Cys SDV rHA and corresponding wild-type rHA from
the H3 A/Texas strain. The mouse study was performed
by Josman LLC and included 7 cohorts, three for each
rHA antigen and one for a placebo, with 10 acclimated
Balb/c mice in each cohort. On day 0 and day 21 of the
study, mice were administered a 25 μL intramuscular in-
jection of either the wild-type rHA antigen at one of
three doses (1 μg, 3 μg, or 10 μg) or the corresponding
5Cys SDV antigen at one of three doses (1 μg, 3 μg, or
10 μg). The placebo group received an equal volume
dose of the formulation buffer. Pre-immune serum sam-
ples collected on day 0 were tested alongside serum
samples collected on day 42 in the HAI assay (see above)
using both the wild-type rHA and SDV rHA as the test
antigens. The number of responders having at least a 4-
fold change in geometric titer on day 42 compared toFigure 9 A and B Pre-clinical mouse immunogenicity study results. Se
antigen (B1-B3) and with the H3 A/Texas wild-type rHA antigen (A1-A3) we
rHA antigen (Panel A, left) and the H3 A/Texas wild-type rHA antigen (Pane
for the day 0 titer.day 0 were similar for all test groups receiving the two
different rHA antigens regardless of the antigen used in
the assay (wild-type or 5Cys SDV). Further, the average
geometric mean titers for all groups were comparable
regardless of the antigen and dose delivered to the mice
(Figure 9). Based on the results, C-terminal cysteine sub-
stitutions and the degree of disulfide cross-linking do
not impact the levels of antigen-specific antibody re-
sponses upon immunization.
Discussion
The influenza HA protein is an integral membrane protein
and the primary target for inducing neutralizing antibodies
to influenza virus. When purified to homogeneity, the pro-
tein forms a rosette structure which exposes the immuno-
genic, trimeric ectodomain, while the transmembrane
domains and short cytoplasmic tails are most likely buried
inside the rosette structure [37]. It has long been demon-
strated that formation of trimeric HA is not dependent on
the TM or CT domains [38], though it has been suggested
that the TM domain may contribute to the stability of the
trimer [37]. Similarly, the early stages of HA mediated
membrane fusion are unaffected by deletion of the TM
and CT domains and replacement by a non-proteinaceous
GPI anchor [39-42]. Therefore, the wild-type rHA and the
TM and CT cysteine SDVs in this study are expected to
form similar trimers and rosettes.
An evaluation of the human influenza strains which
fall into 3 subtypes, H1N1 (H1), H3N2 (H3) and, B,
shows that the H3 rHAs have five cysteine residues in
the TM and CT domains (Figure 1A). The two cysteine
residues in the CT domain are highly conserved and are
found in all human influenza strains. The cysteinera samples from mice immunized with the H3 A/Texas 5Cys SDV rHA
re tested in the HAI assay using both antigens, the H3 A/Texas 5Cys
l B, right). In each plot, the dotted line represents 4× the mean value
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CT is found in H3 and H1 HAs, but not in B HAs. The
biological role of these cysteine residues has been the sub-
ject of several studies which have identified them as sites
of palmitoylation/acylation involved in membrane fusion
and viral replication [25-28]. While these activities are in-
dispensable for the virus, they are not required for expres-
sion and purification of the recombinant hemagglutinin
protein during vaccine manufacture. In fact, replacing all
five of the TM/CT cysteines in the 5Cys SDV or different
subsets of them in the 3Cys and 2Cys SDVs (Figure 1B) re-
sult in rHA proteins having starting yields, final purities,
and purified yields that are comparable to or better than
the wild-type rHA protein (Table 1 and Figure 2A). In con-
trast, substitution of the two conserved cysteine residues
in the globular head domain of the rHA protein, C64 and
C76, with serine residues results in low expression further
confirming that the cysteine residues in the globular head
domain play a critical role in the folding of hemagglutinin
protein, and cannot be substituted (Table 1).
The folding and functional activity of the wild-type rHA
and the TM/CT SDVs were compared by evaluating the
trypsin resistance profiles, and hemagglutination activities.
Trypsin resistance is a property of properly folded trimeric
HA proteins, while hemagglutination requires the orga-
nization of these trimers into higher order rosette struc-
tures that can interact with red blood cells through their
sialic acid and form a lattice like network. Trypsin treat-
ment cleaves properly folded, full-length, trimeric HA into
two fragments, an amino-terminal HA1 fragment and
a carboxy-terminal HA2 fragment, while denatured or
monomeric rHA is digested by the endoprotease. Trypsin
treatment of the wild-type and SDV rHAs results in the
same characteristic HA1 and HA2 cleavage with apparent
molecular weights of ~50 kDa for HA1 and ~28 kDa for
HA2 (Figure 2B). Hemagglutination occurs when the red
blood cells interact via their sialic acid moiety with HA ro-
settes, and form a lattice like network that remains in sus-
pension. In the absence of hemagglutination, the cells do
not form the lattice like network, and a halo or circle of
settled cells is observed. These results demonstrate that
the hemagglutination activity of SDVs of rHA is com-
parable to the wild-type rHA (Table 2). Further, these
results suggest that the cysteine substitutions in the
TM/CT domains do not impact the functional activity
of H3 SDV rHAs.
Having established proper folding and function, the par-
ticle size and thermal stability of the wild-type and SDV
rHA proteins were determined. The average particle size
by DLS (Table 3) for the wild-type rHA and the TM/CT
SDVs is in the range expected for rosettes structures. The
volume mean diameter of the 3Cys and 5Cys SDVs is
35 nm and 37 nm, respectively, compared to 39 nm for
the wild-type H3 rHA protein. The diameter of theparticles for the 2Cys SDV is consistently 10 nm larger
than the wild-type, and may reflect that the replacement
of cysteine to serine at position 523 is not optimal and
leads to particles of larger size. By EM (Figure 3B), the ro-
settes of the wild-type and SDV rHAs are strikingly simi-
lar, and indistinguishable in terms of size and appearance.
In addition to particle size and morphology, the thermal
stability of the rosettes in the SDV rHAs as measured by
DSF is similar to that of the wild-type rHA (Table 4). The
largest difference in Tm, observed between the 5Cys SDV
and the wild-type, is only 1.6°C. Decreased thermal stabil-
ity has been reported previously for three H3 HA variants
in which one or both of the two TM cysteine residues
unique to this subtype were modified [29]. However, the
thermal stability in this study was determined in a fun-
damentally different way on crude extracts using the
hemagglutination activity assay. Further, our thermal sta-
bility data are in close agreement with previously report
TM values for rosettes suggesting that both the WT and
Cys SDV rHAs are similarly highly stable [43].
By SEC, all the rHA proteins have a single, primary
peak with retention times differing by 0.5 minute or less.
In addition, the wild-type and SDV rHAs elute before
the largest standard, thyroglobulin, having an approxi-
mate molecular weight of 660 kDa (Figure 4A). These
data also suggest that the rHA trimers assemble into ro-
settes structures, and the ability to form the rosettes is
unaffected by the cysteine substitutions in the TM/CT
domains. Differences in the homogeneity of the rosette
population in the wild-type and 5Cys SDV rHAs are de-
tected by UPLC SEC analysis of the Zwittergent 3–14
treated rHA (Figure 4B). The Zwittergent 3–14 surfac-
tant efficiently converts the rosettes of the 5Cys SDV,
but not of the wild-type rHA, to trimers. Due to its
smaller size compared to the rosette, the rHA trimer
elutes off the SEC column later and the peak is shifted.
In contrast, Zwittergent 3–14 treatment of the wild-type
rHA protein results in multiple peaks corresponding to
rosette, trimer, and various species of intermediate sizes.
Disulfide mediating cross-linking occurs readily in the
wild-type rHA based on SDS-PAGE analysis (below),
and the various cross-linked states of the protein result
in multiple elution peaks as the Zwittergent 3–14 surfac-
tant cannot disrupt the disulfide bonds.
Though the overall folding, thermal stability, size, and
morphology are the same for the wild-type and TM/CT
SDVs, differences in the formation of disulfide mediated
cross-linked structures have been observed by SDS-
PAGE (Figure 6A). Disulfide mediate cross-linking oc-
curs readily at the C-terminus of the HA molecule
through free cysteines located in the TM and CT do-
mains. In the wild-type rHA and 2Cys SDV rHA, this
cross-linking occurs during the purification process and
is extensive. Cross-linked dimers, trimers, as well as
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diately following purification on day 0, albeit at a slightly
reduced level in the 2Cys SDV. In the presence of redu-
cing agent, the oligomers are converted to monomeric
HA0 confirming that the cross-linking is disulfide medi-
ated and due to the oxidation of free cysteine residues.
Cross-linking of the 5Cys SDV rHA is not observed even
after 28 days at room temperature, while cross-linked di-
mers and trimers of the 3Cys SDV rHA are first ob-
served on the day 28 time point (SDS-PAGE gels for
days 7 and 21 not shown). The non-reducing and redu-
cing SDS-PAGE results for the 5Cys SDV and corre-
sponding wild-type rHA from the H3 A/Texas strain
further support the findings obtained with the H3 A/
Perth SDVs (Figure 8). The formation of non-native di-
sulfide bonds is prevented in H3 rHA proteins by re-
placing all five TM and CT cysteine residues.
Based on the SDS-PAGE results, the rHA protein is
highly susceptible to oxidation through cysteines in both
the TM and CT domain. The subset of cysteines modi-
fied in the 3Cys SDV (C539, C546, and C549) appears to
be more susceptible to cross-linking than the subset of
cysteines in the 2Cys SDV (C524 and C528). The latter
two substitutions have little effect on the SDS-PAGE
profile of the 2Cys SDV compared to the wild-type rHA,
while the former three substitutions markedly reduce
the formation of cross-linked rHA in 3Cys SDV. These
results are not unexpected as the cysteines in the CT
domain are more exposed at the C-terminus of the mol-
ecule. Free cysteine at this position may permit the
cross-linking of monomers within a given trimer (intra-)
and between monomers of different trimers (inter-).
The RP-HPLC profiles for H3 A/Perth rHAs (Figure 7)
and the H3 A/Texas rHAs (Figure 8) are consistent with
the non-reducing SDS-PAGE analyses. The multiple elu-
tion peaks observed for the wild-type rHAs and 2Cys
SDV rHAs may be due to different cross-linked popula-
tions. Alternatively, they may due to the covalent attach-
ment of fatty acids (palmitate and/or stearate) through
thio-ester linkages involving the last three C-terminal
cysteine residues present in both of these rHA molecules
[26,44], but absent in the 3Cys and 5Cys SDV rHA pro-
teins. Both types of populations, cross-linked rHA and
acylated rHA, are more likely to be retained on the col-
umn due the increased hydrophobic character and elute
later in the gradient as observed here in the RP-HPLC
profiles for the wild-type and 2Cys SDV rHA.
Concurrent with evaluation of the cross-linking, the
potency of the wild-type and SDV rHA proteins from
the H3 A/Perth and H3 A/Texas strains were measured
by the SRID assay (Figures 5 and 8). By this method, the
relative potency is directly proportional to the number
of TM/CT substitutions and inversely correlated with
cross-linking. In the 5Cys SDV rHA in which all fiveTM/CT cysteines have been replaced, the potency rela-
tive to day 0 remains at 100% even after 12 months at
room temperature for both the H3 A/Texas and H3 A/
Perth 5Cys SDV rHAs, and no disulfide mediated cross-
linking is observed. By comparison, the relative potency
of the wild-type H3 rHAs drop approximately 75% after
4 weeks of storage at 25°C, and demonstrates extensive
cross-linking. Compared to the wild-type rHAs, relative
potency of the 2Cys SDV (two TM cysteine substitutions
in H3 A/Perth rHA) drops to 50% during the same time
(4 weeks at 25°C). Furthermore, the relative potency of
the 3Cys SDV (three cysteine substitutions in the TM
and CT domains of H3 A/Perth rHA), drops only 20%
after 4 weeks storage at 25°C. While cross-linking is
markedly reduced for the 3Cys SDV rHA, the 2Cys SDV
shows only a marginal improvement over the wild-type
rHA protein. These results clearly demonstrate that the
substitution of cysteine residues in the CT domain has a
significant impact on potency, but substituting cysteine
residues in both the TM and CT domains has a synergis-
tic effect on potency of the rHA.
While including a reducing agent and redox buffer,
STG and Citrate, in the formulation buffer has been
shown to prevent an apparent potency loss associated
with the formation of non-native disulfide bonds and
higher order cross-linked oligomers of the HA (manu-
script in preparation), the results of this study clearly
show that replacing the five cysteines in the TM and CT
domains with an alternative amino acid has the same ef-
fect and is a highly effective alternative solution to ad-
dress potency loss. The ability of these cysteines to
cross-link appears to be a direct consequence of the pro-
duction and purification process that releases the TM
domain from the constrained environment of the mem-
brane bilayer and the CT domain from the reducing en-
vironment of the cell. Since the three dimensional
structure of the C-terminus (TM and CT domains) has
not been solved by X-ray crystallography, a theoretical
structural analysis of HA using a membrane protein top-
ology prediction algorithm was performed assuming that
the transmembrane region of the HA molecule adopts
and continues the alpha- helical conformation of the
proceeding HA2 domain [15]. Using the program
TMHMM [45,46] and the HA sequence from H3 A/
Perth, seven symmetrical alpha helical trimer configura-
tions are possible (see Figure 10). Based on this model,
the TM and CT cysteines are in the correct orientation
and geometry to form both intra-molecular cross-links
within a trimer and inter-molecular cross-links between
different trimers. Amino acids with a spacing of three or
four may be found on the same face of an alpha helix
and cysteine residues in those positions can form disul-
fide bonds between two adjacent helices, thus covalently
linking helices. Cysteine residues on the outside of the
Figure 10 Modeling of the TM and CT domains in the HA trimer. The top shows the amino acid sequence of the carboxy terminus (TM and
CT domains) for H3 A/Perth HA with the TM and CT cysteines highlighted in yellow (top line), and the 7 possible orientations of that sequence in
a helix with the interfacial positions highlighted in pink (A and D). The schematics depict the trimer configuration (each monomer is represented
by a seven pointed helical wheel) with 7 positions labeled A through G on the bottom left and one possible configuration (orientation 2) on the
bottom right.
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higher order oligomers. The association of HA trimers
through their hydrophobic transmembrane domains in
rosette structures also facilitates intermolecular cross-
linking by positioning the C-terminal cysteines from dif-
ferent trimers in close proximity to each other.
While both intra- and inter-molecular cross-linking of
the HA trimer are possible, the latter may reduce diffu-
sion, and/or antibody recognition in the SRID assay.
Prior to analysis in the SRID assay, the rHA proteins are
pre-treated with Zwittergent 3–14 surfactant into order
to dissociate non-covalently bound rHA rosettes struc-
tures into soluble trimers. SEC-UPLC analysis of rHA
before and after Zwittergent 3–14 treatment clearly
shows that only a portion of the wild-type rosettes are
converted to trimers; in contrast, the rosettes of the
5Cys SDV are quantitatively converted to trimers. Due
to their small size (~12-14 nm in length, its longest di-
mension), rHA trimers can readily diffuse in to the agar-
ose gel containing antibody and the size of the resulting
precipitin ring is directly proportional to the antigen
concentration. In contrast, trimers covalently bound to-
gether in rosettes through disulfide bonds are resistant
to Zwittergent 3–14 pre-treatment. Depending on the
extent of oxidation and/or the orientation of the cross-
linked trimers, mobility of the particles through the gel
may be hindered resulting in artificially small ring sizes.Alternatively, access to the epitopes may become in-
creasingly hindered as the rosettes become covalently
cross-linked through disulfide bonds resulting in a re-
duction in antibody binding and signal. Due to the in-
ability of the SRID assay to accurately measure the
rosette in a cross-linked state, an artificial or apparent
potency loss is observed as the number of these oxidized
species increases with storage of the rHA protein.
HA rosettes have been considered an indicator of
immunogenicity because of their resemblance to the in-
fectious influenza virions having HA trimeric spikes pro-
truding from the viral envelope [36]. Additionally, the
antigenic sites on the HA molecule responsible for elicit-
ing neutralizing antibodies are located in the globular head
domain approximately 135 Å away from the cysteine sub-
stitutions located at the opposite end of the elongate mol-
ecule in the TM and CT domains [9-11]. Despite this wide
physical separation, structural perturbations from side
chain mutations have been shown to be propagated over
long distances through the peptide backbone. For this
reason, the antigenic and immunological affects of C-
terminal substitutions on the rHA protein were de-
termined. The hemagglutination inhibition assay was
performed using the SDV and wild-type H3 A/Perth rHA
proteins in order to determine and compare recognition
and binding to antibodies in sera produced using the wild-
type rHA antigen. The HAI titers for the SDVs were
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the antigenic presentation of the epitopes on the SDVs has
not been changed by the cysteine substitutions. Also, mice
were immunized with either the H3 A/Texas 5Cys SDV or
the corresponding wild-type rHA antigen. Based on
similar HAI titers obtained in each group, the cysteine
substitutions have no effect on the levels of rHA-specific
antibody responses induced upon immunization. Thus,
the cross-linked trimers in the wild-type rHA rosettes and
the un-cross-linked trimers in the 5Cys SDV rHA rosettes
induce comparable antibody responses in mice upon
immunization. The results suggest that the potency loss
observed for the wild-type rHA protein over time is
largely due to the inability of the required potency assay to
measure higher order cross-linked forms of the protein
that retain their immunogenicity. Future work will include
clinical trials to determine the impact on immunogenicity
in human subjects.
In the manufacture of the rHA vaccine, the unique
(non-biological) environment permits the formation of
non-native disulfide bonds through free cysteines located
in the TM and CT domains of the wild-type rHA pro-
tein. C-terminal cross-linking may occur to some extent
in traditional split and subunit influenza vaccines as the
purification process uses a detergent extraction step
which may liberate the C terminus of the HA from the
viral membrane. While both inter- and intra-molecular
cross-linking can occur, only the latter results in cross-
linked rosette structures that remain immunogenic, but
are not accurately measured in the SRID assay. As a re-
sult, an apparent potency loss is observed with storage
of the wid-type rHA vaccine. Cysteine mutagenesis is
one way to overcome protein oxidation without the
introduction of reducing agents in the formulation.
However, the utility of this strategy is largely limited to the
recombinant influenza vaccine since site specific mutagen-
esis of the virus prior to amplification in chicken cells or
mammalian cells would represent a significant challenge.
Conclusions
rHA proteins form higher-order, defined oligomers (ro-
settes) that become covalently cross-linked through cyst-
eine residues in the TM and CT domains. Replacement of
these cysteine residues prevents disulfide bond formation
at the C-terminus, but does not impact the expression,
purification, or folding of the molecule based on our work
as well as others [28,29]. Moreover, the particle size and
morphology, thermal stability, and antigenicity of the mol-
ecule are unaffected. Application of the cysteine mutagen-
esis strategy to rHA proteins derived from the other
seasonal influenza subtypes (H1 and B), and pandemic
strains (H5N1, H7N7) is currently underway, and a clinical
trial is being planned. This technology may be extremely
important for pandemic preparedness and would greatlyenhance the value of the stock pile if the vaccine is not
subject to potency loss at room temperature.
Methods
Generation of cysteine variants of rHA by site-directed
substitution
The polymerase chain reaction (PCR) was used to con-
struct three plasmid DNA constructs encoding different
variants of the H3 A/Perth/16/2009 (H3 A/Perth) wild-
type rHA protein. Amino acid residue changes were
introduced by two complementary site directed muta-
genesis (SDM) primers which contain sense mutations
of the nucleotide(s). Table 6 provides the sequences of
the SDM primers for the different variants with the nu-
cleotides designed to introduce mutations in bold lower
case type. The pPSC12 LIC transfer plasmid DNA, a
proprietary transfer vector from PSC, containing the
wild-type HA gene for the H3 A/Perth rHA protein was
used as a template in the PCR for all constructs but one.
The mutagenized DNA from the PCR for the triple mu-
tation (C539A, C546A, and C549A) was used as a tem-
plate in a subsequent PCR to generate the construct
containing the TM and CT mutations, C539A, C546A,
C549A, C524A, and C528A. The PCRs were treated with
the restriction endonuclease DpnI to digest the template
DNA, and transformed into E. coli. Plasmid DNA was
isolated for sequencing. Sequencing analysis was per-
formed using HA specific primers to confirm substitutions
of the targeted amino acid residues. The PCR strategy de-
scribed above was also used to substitute the five cysteine
residues in the TM and CT domains of the H3 A/Texas
rHA protein (C524A, C528A, C539A, C546A, C549A).
The DNA containing corresponding H3 A/Texas triple
cysteine substitutions (C539A, C546A, C549A) was used
as the template in the PCR (Table 6).
Baculovirus generation and scale-up
The parental AcMNPV baculovirus (AcB729.3) DNA
was linearized to remove the polyhedrin gene and 3′
region of ORF1629, and subsequently co-transfected
with the plasmid DNA containing the rHA gene of
interest into expresSF+ (SF+) cells. The culture was incu-
bated for ~5 days at 27°C with shaking prior to harvesting
by centrifugation. The resulting viral supernatant post
transfection was used to infect a monolayer of SF+ cells to
purify and isolate recombinant plaques for further scale-
up. Briefly, monolayers of SF+ cells in early to mid-log
phase were inoculated with serial dilutions of the trans-
fection supernatant. A 2× Protein Sciences Formulation
Medium (PSFM)/Agarose overlay was applied to the
plates. After 8 days at 27°C, well isolated recombinant
baculovirus plaques were identified by microscopic evalu-
ation under low magnification and by comparison with a
control of wild-type baculovirus plaques with polyhedra.
Table 6 Primers for SDV rHA proteins of H3 A/Perth and 5Cys SDV rHA of H3 A/Texas
Substitutions (SDV) Primers (5′ to 3′)
H3 A/Perth
C524S, C528A (Control SDV) forward CCTTTGCCATATCATcTTTTTTGCTTgcTGTTGCTTTGTTGGGG
reverse CCCCAACAAAGCAACAgcAAGCAAAAAAgATGATATGGCAAAGG
C539A, C546A,C549A (3Cys) forward GGGGTTCATCATGTGGGCCgcCCAAAAAGGCAACATTAGGgcCAACATTgcCATTTAAGTAAGTACCG
reverse CGGTACTTACTTAAATGgcAATGTTGgcCCTAATGTTGCCTTTTTGGgcGGCCCACATGATGAACCCC
C539A, C546A, C549A, C524A, C528A (5Cys)* forward CCTTTGCCATATCAgcTTTTTTGCTTgcTGTTGCTTTGTTGGGG
reverse CCCCAACAAAGCAACAgcAAGCAAAAAAgcTGATATGGCAAAGG





C539A, C546A, C549A (3Cys) forward CATCATGTGGGCCgcCCAAAAGGGCAACATTAGGgcCAACATTgcCATTTGATAAGTAA
reverse TTACTTATCAAATGgcAATGTTGgcCCTAATGTTGCCCTTTTGGgcGGCCCACATGATG
C524A, C528A, C539A, C546A, C549A (5Cys)* forward TCCTTTGCCATATCAGcTTTTTTGCTTgcTGTTGCTTTGTTGGGG
reverse CCCCAACAAAgcAACAGCAAGCAAAAAAgCTGATATGGCAAAGGA
*DNA for the corresponding triple mutation (3Cys) was used as the template for the PCR reaction.
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to infect a culture of SF+ cells. The infected culture was
incubated for at least 5 days at 27°C with shaking and was
harvested by centrifugation. The supernatant containing
the passage 1 (P1) virus was further amplified to passage 5
virus by propagation of P1 virus through P5 in SF+ cells
serum-free PSFM. The viral supernatants were harvested
by centrifugation to generate the virus stocks for infection.Production and purification of rHA proteins
The recombinant P5 baculovirus stocks were used to pro-
duce the wild-type and variant rHA proteins. Cultures of
SF+ cells (10 L) were seeded in PSFM media and main-
tained at 26-28°C with agitation in glass bioreactors
equipped with an air overlay, and a desired dissolved oxy-
gen concentration. After reaching a density of ~ 2.0-2.5 ×
106 cells/mL, the culture was infected by adding 2% (v/v) of
the P5 working virus stock. The infected cultures were har-
vested approximately 56 hours post infection when the cell
viability reached 40%-50%. The cell pellets were collected
by centrifugation for further purification and analysis.
The rHA protein was solubilized from the SF+ cell
membrane using Triton X-100 surfactant and released
into a buffer for further purification. Cell debris and sus-
pended solids were removed from the cell extract by
depth filtration. The rHA in the filtrate stream was con-
centrated by ion exchange chromatography, and further
purified from process related impurities using a hydro-
phobic interaction column followed by Q membrane fil-
tration. Tangential flow filtration was used for final
buffer exchange into phosphate buffered saline (PBS).
The proteins were diluted, if necessary, to a final totalprotein concentration of 400–600 μg/mL. The purified
rHA proteins were filtered through a 0.2 μm filter and
stored at 4°C until further use.Stability testing and biochemical and biophysical
characterization of rHAs
The purified H3 A/Perth wild-type and SDV rHA proteins
were stored under accelerated conditions by placing the
samples at 25°C. Aliquots were removed on days 0, 7, 14
or 21, and 28 in order to determine potency by SRID,
cross-linking by SDS-PAGE, and hydrophobicity by RP-
HPLC. Additional potency measurements were made at
approximately 2.5, 6, 9 and 12 months. Proper folding and
functional activity were assessed by the trypsin resistance
and hemagglutination assays (HA), respectively. Particle
size was determined by Dynamic Light Scattering (DLS)
and Size Exclusion Chromatography (SEC), thermal stabil-
ity by Differential Scanning Fluorimetry (DSF), and antige-
nicity using the hemagglutination inhibition (HAI) assay.
The purified H3A/Texas 5Cys SDV and corresponding
wild-type rHA proteins were stored under both acceler-
ated (25°C) and real time (5°C) storage conditions. These
rHA proteins were monitored for potency by SRID,
cross-linking by SDS-PAGE, and hydrophobicity by RP-
HPLC on a monthly basis for four months.Total protein measurements
Total protein was determined by the bicinchoninic acid
method (BCA) using the BCA protein assay kit (Cat#23225,
Thermo Scientific, Rockford, IL) following the manufac-
turer’s recommendations.
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SDS-PAGE was performed under both reducing and
non-reducing conditions. The rHA samples were mixed
with 2× Laemmli buffer (Bio-Rad, 161–0737), and ap-
proximately 4-5 μgs of rHA was loaded per lane. For re-
ducing conditions, a final concentration of 100 mM DTT
was added to the Laemmli-rHA solution using a 500 mM
DTT stock (Pierce, product# 20291, lot# ND170603) and
incubated in a 100°C heat block for 3–5 min prior to load-
ing on to the gel. Non-reduced and reduced samples were
separated using either 3-8% Tris-Acetate gels (Life Tech-
nologies, EA03752BOX) and Tris-Acetate SDS Running
Buffer (Invitrogen, LA0041) or 4-12% NuPAGE Bis-Tris
Gels (Cat# NP0323, Life Technologies Corporation,
Carlsbad, CA) and 1× MES Running Buffer (50 mM MES,
50 mM Tris, 0.1% sodium dodecyl sulfate, 1 mM EDTA
pH 7.3) at 150 volts for 1 hour. Protein bands were visual-
ized by Coomassie staining (Bio-Rad, 161–0787). Gels were
stained for 1 hour followed by a water wash until protein
bands developed. Alternatively, purity and trypsin resist-
ance gels were stained for 1 hour in 0.1% Brilliant Blue R,
7.7 M reagent alcohol, 1.75 M glacial acetic acid, and de-
stained in 10% acetic acid. Gels were scanned using Gel
Logic 212 Pro Imaging System, and densitometry was per-
formed using the Carestream Molecular Imaging software
(Carestream Health, Incorporated, New Haven, CT).
Trypsin resistance assay (TR)
Purified rHA proteins at a total protein concentration of
250 μg/mL were analyzed both with and without heat
denaturation (5 minutes at 100°C) for trypsin resistance.
The samples were incubated in the presence or absence
of 50 μg/mL trypsin (Cat#T1426, Sigma) for 30 min at
2-8°C. Digestion was stopped by incubating the samples
in 2× disruption buffer (120 mM Tris pH 6.8, 20% gly-
cerol, 4% sodium dodecyl sulfate, 0.2% bromophenol
blue, 200 mM dithiothreitol) in a 100°C heat block for
3–5 minutes. Samples were analyzed by SDS-PAGE as
described above.
Hemagglutination assay (HA)
The hemagglutination assay was performed in 96 well u-
bottom microtiter plates (Corning Inc., Part# 2797).
Each monovalent bulk batch was loaded at a total pro-
tein concentration of 1 μg/mL in the first lane, and two-
fold serial dilutions were performed in 1 × PBS across
the plate. An equal volume of fresh, washed guinea pig
red blood cells (RBCs) (Lampire Biological Labs, Cat#
7243108) at a concentration of 0.5% in 1 × PBS was
added to each well. After approximately 1 hour of incu-
bation at room temperature, the plates were scored for
agglutination of red blood cells in presence of rHA. The
HA activity of the purified rHA is defined by the dilution
at which partial agglutination was observed (i.e., 50% ofthe RBCs were agglutinated or the pellet appeared loose).
If only fully agglutinated and/or tight pellets were
observed, the endpoint was defined as the average of
the dilutions at which agglutinated and tight pellets
were observed.
Size exclusion chromatography (SEC)
Size exclusion chromatography (SEC) was performed on a
Waters Alliance 2695 HPLC system (SEC-HPLC) with a
PDA detector using a Biosuite 450, 8 μm HR SEC column
(7.8 × 300 mm) (Waters; Cat#186002166) or a Waters H-
Class Bio UPLC system (SEC-UPLC) with PDA detector,
using an acuity BEH 450 chromatography column. The
latter system was used to analyze select rHAs including
the wild-type and 5Cys SDV before and after pre-
incubation with 1% Zwittergent 3–14, the surfactant used
to pre-treat rHA samples for the SRID potency assay. For
all SEC analyses, the mobile phase consisted of 1 × PBS
pH 7.2 with 300 mM NaCl and a flow rate of 0.25 mL/
min was used. Approximately 17.5 μg of rHA was injected
per sample. Columns were calibrated by analyzing the
proteins in a gel filtration HMW calibration kit (Cat# 28-
4038-42, GE Healthcare Piscataway, NJ), and a standard
curve was generated. The data were analyzed using the
Empower 2 Chromatography Data Software (Waters
Corporation, Milford, MA).
Dynamic light scattering (DLS)
Dynamic Light Scattering was performed using a Malvern
Zetasizer Nano-S (Malvern Instruments, Worcestershire,
UK) according to the manufacturer’s instructions. Zetasizer
software (Version 6.20) was used for data analysis. Each
purified rHA protein was analyzed undiluted at a total
protein concentration between 400–600 μg/mL. A 70 μL
aliquot of each rHA was dispensed into a micro-cuvette
and measured in duplicate. Each measurement consisted
of 12–14 individual scans. The volume-average size distri-
butions from each set of scans were averaged for a given
rHA.
Electron microscopy (EM)
Negative staining scanning electron microscopy was per-
formed by Paragon Bioservices. Samples were prepared
using a continuous carbon grid method, using 400-mesh
copper grids with a nitrocellulose film. The rHA proteins
were diluted 5-fold in water, applied to the grid, and imme-
diately stained with uranyl formate solution (1%). Electron
microscopy was performed at room temperature. Ten im-
ages were obtained for each rHA at a magnification of
135,000 × .
Differential scanning fluorimetry (DSF)
DSF was performed using a fluorescent dye (ProteoStat,
Enzo Life Sciences) and a real time PCR machine (Applied
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were scanned from 25°C to 99°C, and the fluorescence in-
tensity was monitored as a function of temperature. The
temperature where rHA unfolded (characterized by a tran-
sition in the fluorescence signal) was determined from the
second derivative plot, and expressed as midpoint transition
temperature (Tm). The Tm is the temp where 50% of the
molecules are in the unfolded state. The data were analyzed
using the Applied Biosystems Protein Thermal Shift
Software (Version 1.1).
Reverse phase (RP) HPLC analysis
RP-HPLC was performed using a polystyrene POROS R1/
10 (2.1 mm× 100 mm) column (Applied Biosystems, 1-
1012-16) on a Waters Alliance 2695 HPLC system with a
PDA detector. Mobile phase A consisted of 0.1% trifluor-
oacetic acid, 5% acetonitrile in water (Solvent A), and mo-
bile phase B consisted of 0.1% trifluoroacetic acid in
acetonitrile (Solvent B). The column was pre-equilibrated
in 20% B. The following mobile phase gradient was
applied to each sample: 2 min 20-40% B, 1 min 40% B,
7.5 min 40-100% B, and 3.5 min 100% B. A flow-rate of
0.8 mL/min was used and the absorbance was monitored
at 214 nm. To prevent carry-over between samples, the
column was washed after each sample by injecting 1%
Zwittergent (100 μL) on to the column and applying the
following wash gradient: 100-20% B, 8 minutes. The rHA
samples were pre-treated for 30 minutes with 25 mM
DTT using a 500 mM DTT stock, and were filtered using
0.45 μm syringe filter units (Millipore, SLVR04NL) prior
to RP-HPLC analysis using Empower 2 Chromatography
Data Software (Waters Corporation, Milford, MA). Each
sample was analyzed in duplicate using approximately
20 μg of rHA per injection.
In vitro potency measurements
The rHA potency was determined by the SRID assay as
described previously [19,20]. Briefly, rabbit polyclonal anti-
serum for the wild-type H3 A/Perth rHA antigen was
added to melted 1% agarose (Cat# 50010, SeaKemME,
Lonza, Rockland, ME ) in 1 × PBS (pH 7.2) (Cat# 20012–
050, Life Technologies Corporation) at 54-56°C and
allowed to solidify at ambient temperature on GelBond
film (Cat# 53734, Lonza, Rockland, ME). Wells of 4 mm
in diameter were punched into the gels and serial dilutions
of both the reference standard of known potency, and the
purified rHA antigens were loaded. Reference and sample
proteins were incubated with Zwittergent 3–14 (Cat#
693017, Calbiochem, Darmstadt, Germany) at a final con-
centration of 1% for at least 30 minutes prior to preparing
the serial dilutions in 1 × PBS containing 1% Zwittergent
3–14. The gels were placed in a sealed moist chamber at
room temperature for ~18 hours. Following incubation, the
gels were washed first with 1 × PBS (pH 7.2) and then withwater. The gels were allowed to dry prior to staining with
Coomassie Brilliant Blue R250 (Cat#BO149, Sigma). The
gels were then destained and dried again for analysis. The
diameters of the precipitin rings were measured in two or-
thogonal directions using the GT Vision SRID Reading
Program (GT Vision LLC, Hagerstown, MD). Recombinant
HA potency was calculated in μg/mL by the parallel line
bioassay method using reference and test rHA antigen re-
sponse curves (log antigen dilution vs. log zone diameter).
Statistical parameters for determining test validity were
based on correlation coefficients (r ≥ 0.95) and the equality
of slopes (t < 4.604) between test and reference antigens.
Hemagglutination inhibition (HAI)
The HAI assay was performed in 96-well u-bottom mi-
crotiter plates. Each rHA antigen was standardized to
have an HA titer of 4 HA units/25 μL (this titer provides
four wells of hemagglutination activity). The standard-
ized preparations of diluted rHA were then mixed with
2-fold serially diluted antibody. Mouse serum samples
were pre-treated with receptor destroying enzyme (RDE
(II) “SEIKEN”, Denka Seiken Co., LTD., Japan) prior to
testing to remove non-specific binding of the rHA anti-
gen. The antigen and antibody were allowed to incubate
for approximately 15 minutes prior to the addition of an
equal volume of 0.5% guinea pig red blood cells. Plates
were incubated at ambient temperature for approxi-
mately 45 minutes to 1 hour, the time required for the
cells to completely settle in the absence of any hemag-
glutinating activity (negative control lane) in PBS buffer.
The HAI titer, the reciprocal of the last dilution of anti-
serum that completely inhibits hemagglutination, was de-
termined. The assay was performed using two polyclonal
antisera: rabbit polyclonal anti-H3 antibody generated
against BEVS derived wild-type H3 A/Perth rHA and
sheep polyclonal anti-H3 antibody generated against bro-
melain cleaved HA derived from the H3/Victoria/361/
2011 influenza virus propagated in eggs. A reference anti-
gen from Center for Biologics Evaluation and Research
(CBER) for H3 A/Perth/16/2009 HA (lot# 70) was in-
cluded in the assay for comparison to the rHA proteins.
Mouse study
The antigen formulations were shipped to Josman LLC
for immunization of acclimated Balb/c mice (10 mice
per cohort). The mice received a 25 μL intramuscular in-
jections on day 0 and day 21. The mice in the control
antigen cohorts, A1, A2, and A3, received 1, 3, and
10 μg of the wild-type H3 A/Texas rHA. The mice in
the test antigen cohorts, B1, B2, and B3, received 1, 3,
and 10 μg of the H3 A/Texas 5Cys SDV rHA. The mice
in the placebo cohort C were administered a 25 μL
intramuscular injection of formulation buffer. Blood
(~250 μL) was collected from each mouse before the
Holtz et al. BMC Biotechnology  (2014) 14:111 Page 19 of 20first injection on day 0 and at the end of the study on
day 42. The blood was allowed to clot for approximately
2 hours at ambient temperature prior to centrifuging to
isolate the sera in the supernatant. The sera samples
were stored frozen at −20°C until testing in the HAI assay.
This study was performed under protocol JLP-005.010 by
Josman LLC, a licensed research facility (USDA license
number 93-R-0260; OLAW-NIH/PHS Assurance license
number A3404-01) that adheres to guidelines set forth
through the Animal Welfare Act (7 U.S.C. 2131 et seq.),
and through the Office of Laboratory Animal Welfare of
the National Institutes of Health.
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